Matthew Baker
Direttore/Membro del Consiglio presso FUSION ANTIBODIES PLC
Patrimonio netto: 7 459 $ in data 31/05/2024
Profilo
Matthew Paul Baker was the founder of Abzena (Cambridge) Ltd., which was founded in 2004, where he held the title of Chief Scientific Officer & Director until 2016.
He is currently the Chief Executive Officer at NeoPhore Ltd.
since 2020 and a Non-Executive Director at Fusion Antibodies Plc since 2022.
Dr. Baker's former positions include Non-Executive Director at Oxford Genetics Ltd.
and Mercia Asset Management Plc, Executive Vice President-Biologics Discovery at Biovation Ltd., and Chief Scientific Officer at PolyTherics Ltd.
He was also the Chief Scientific Officer at Abzena Ltd.
from 2013 to 2016.
Dr. Baker received a doctorate degree from the University of Birmingham.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
FUSION ANTIBODIES PLC
0.16% | 14/02/2024 | 156 250 ( 0.16% ) | 7 459 $ | 31/05/2024 |
Posizioni attive di Matthew Baker
| Società | Posizione | Inizio |
|---|---|---|
| FUSION ANTIBODIES PLC | Direttore/Membro del Consiglio | 01/03/2022 |
NeoPhore Ltd.
 NeoPhore Ltd. Miscellaneous Commercial ServicesCommercial Services NeoPhore Ltd. engages in discovery and development of small molecules inhibitors to treat cancer. The company is headquartered in Kings Cross, London, the United Kingdom. | Amministratore Delegato | 01/01/2020 |
Precedenti posizioni note di Matthew Baker
| Società | Posizione | Fine |
|---|---|---|
| ABZENA PLC | Direttore Tecnico/Scientifico/R&S | 01/10/2016 |
Abzena (Cambridge) Ltd.
 Abzena (Cambridge) Ltd. Miscellaneous Commercial ServicesCommercial Services Abzena (Cambridge) Ltd. provides antibody engineering and immunogenicity screening services. The company was founded in 2004 and is headquartered in Babraham, the United Kingdom. | Fondatore | 01/01/2016 |
| MERCIA ASSET MANAGEMENT PLC | Direttore/Membro del Consiglio | - |
Oxford Genetics Ltd.
 Oxford Genetics Ltd. BiotechnologyHealth Technology Oxford Genetics Ltd. produces modular DNA plasmids for biological research. Its products include DNA systems, kits, and cell lines. The company was founded by Ryan Cawood and Leonard Seymour on April 28, 2011 and is headquartered in Oxford, the United Kingdom. | Direttore/Membro del Consiglio | - |
Biovation Ltd.
 Biovation Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Merck KGaA, Biovation Ltd. is a British company that develops proprietary pharmaceutical and diagnostic agents. The company is based in Aberdeen, UK. Biovation was acquired by Merck KGaA on October 01, 2000 for $29.28 million. | Corporate Officer/Principal | - |
Formazione di Matthew Baker
| University of Birmingham | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| FUSION ANTIBODIES PLC | Health Services |
| MERCIA ASSET MANAGEMENT PLC | Finance |
| Aziende private | 6 |
|---|---|
Biovation Ltd.
Biovation Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Merck KGaA, Biovation Ltd. is a British company that develops proprietary pharmaceutical and diagnostic agents. The company is based in Aberdeen, UK. Biovation was acquired by Merck KGaA on October 01, 2000 for $29.28 million. | Commercial Services |
PolyTherics Ltd.
 PolyTherics Ltd. Pharmaceuticals: MajorHealth Technology PolyTherics Ltd. develops biomedical polymers for therapeutic applications. The company was founded by Antony Godwin, Sunil Shaunak and Steve Brocchini in 2001 and is headquartered in Babraham, the United Kingdom. | Health Technology |
Abzena (Cambridge) Ltd.
Abzena (Cambridge) Ltd. Miscellaneous Commercial ServicesCommercial Services Abzena (Cambridge) Ltd. provides antibody engineering and immunogenicity screening services. The company was founded in 2004 and is headquartered in Babraham, the United Kingdom. | Commercial Services |
Oxford Genetics Ltd.
Oxford Genetics Ltd. BiotechnologyHealth Technology Oxford Genetics Ltd. produces modular DNA plasmids for biological research. Its products include DNA systems, kits, and cell lines. The company was founded by Ryan Cawood and Leonard Seymour on April 28, 2011 and is headquartered in Oxford, the United Kingdom. | Health Technology |
Abzena Ltd.
 Abzena Ltd. BiotechnologyHealth Technology Abzena Ltd. engages in the provision of proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It offers antibody discover and candidate screening, immunology and immunogenicity assessment, antibody and protein engineering, bio conjugation, custom synthesis of cytotoxic payloads, reagents, and other small molecules, manufacture of payload linkers, development of manufacturing cell lines, and manufacture of biopharmaceuticals. The company was founded by Sunil Shaunak in 2001 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
NeoPhore Ltd.
NeoPhore Ltd. Miscellaneous Commercial ServicesCommercial Services NeoPhore Ltd. engages in discovery and development of small molecules inhibitors to treat cancer. The company is headquartered in Kings Cross, London, the United Kingdom. | Commercial Services |
- Borsa valori
- Insiders
- Matthew Baker
